Tirzepatide glaucoma risk was lower than with selective glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback